Abnormal activation of c-Met (by gene amplification, mutation, transloction, or auto-/paracrine ligand signaling) has been linked to the development and progression of many types of cancer, including hepatocellular carcinoma, lung cancer, colorectal cancer, breast cancer, pancreatic cancer, ovarian cancer, prostate cancer, gastric cancer, and GBM (Olmez et al., 2013; Zhang et al., 2018). Here, MET is linked to glioblastoma.